Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases

Aydın, Ömür; Sözener, Zeynep Çelebi; Soyyiğit, Şadan; Kendirlinan, Reşat; Gençtürk, Zeynep; Mısırlıgil, Zeynep; Mungan, Dilşad; Sin, Betül Ayşe; Demirel, Yavuz; Çelik, Gülfem; Bavbek, Sevim

doi:10.2500/aap.2015.36.3909

Cited by 35 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collins et al observed a significant improvement in ACT symptom scores in patients with ABPA after omalizumab treatment (30). Aydın et al reported that compared to the basal score, mean ACT score had increased after starting omalizumab treatment (21). Similar to these two reports, omalizumab treatment improved asthma symptoms and significantly increased the mean ACT score in both the first and third years in our study.…”

Section: Discussionsupporting

confidence: 87%

“…Patients who do not respond to corticosteroids antifungal medication can be used (29). Recently, reports have described effective results with the administration of omalizumab in patients with severe allergic asthma and ABPA (21,29). In our study 5 (33.3%) patients with severe asthma had unsatisfactory response to anti-asthmatic agents.…”

Section: Discussionmentioning

confidence: 49%

“…ABPA is an immunological pulmonary disorder with various clinical, radiological and laboratory features (2) . Published reports about ABPA are limited to case reports and small series in our country (21,23). This is perhaps due to lack of uniform diagnostic criteria.…”

Section: Discussionmentioning

confidence: 99%

“…These patients were followed at 3 months intervals. We considered omalizumab treatment in severe persistent asthma and ABPA patients who have failed to respond to Global Initiative for Asthma step 4 treatment (21). Omalizumab was administered at dosages and dosing frequency based on the patient's weight and initial total IgE levels as recommended for asthma (22).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Allergic Bronchopulmonary Aspergillosis: A Clinical Evaluation of 15 Patients and Successful Omalizumab Treatment of Five Patients

Ünal¹

2019

Asthma Allergy Immunol

View full text Add to dashboard Cite

Objective: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disease caused by hypersensitivity reactions to Aspergillus antigen. Studies on the efficacy of omalizumab treatment in patients diagnosed with ABPA are limited to case reports and small series. Our aim was to evaluate the effectiveness of omalizumab treatment in ABPA in addition to clinical, radiological and serological characteristics these patients. Materials and Methods: This study is a prospective observational one. It included clinical review of 15 patients diagnosed with ABPA and the successful omalizumab treatment of 5 of these patients. Patients receiving omalizumab therapy were assessed at baseline, after 1 year and 3 years of starting treatment. Results: 15 patients (9 males, 6 females, mean age: 48.26 ± 9.92 years) diagnosed as ABPA were enrolled. One patient had received antituberculosis medications prior to diagnosis. The mean serum total IgE level was 1665 ± 909 IU/mL. The most common finding in thorax high-resolution computed tomography was central bronchiectasis. Omalizumab treatment was started in five patients with asthma and ABPA who have failed to respond to Global Initiative for Asthma step 4 treatment. Conclusion: ABPA should be considered in patients with uncontrolled or severe asthma, despite appropriate asthmatic treatment. Recognizing ABPA is important, because early diagnosis can delay the development or prevent the bronchiectasis that causes fibrotic lung disease. Omalizumab is an effective therapy option in patients with asthma and ABPA who fail to respond to Global Initiative for Asthma step 4 treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Allergic Bronchopulmonary Aspergillosis: A Clinical Evaluation of 15 Patients and Successful Omalizumab Treatment of Five Patients

Ünal¹

2019

Asthma Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…They indicate that the serum EDN level may be a useful marker for monitoring persistent airflow limitation in adult patients with allergic asthma who are positive for house-dust-specific IgE antibodies. Also within this issue, Aydın et al 3 report on the potential utility of total serum IgE as a biomarker for responsiveness to omalizumab in patients with allergic bronchopulmonary aspergillosis.…”

mentioning

confidence: 99%